PATHOLOGY, PATHOGENESIS AND EPIDEMIOLOGY OF POLIOVIRUS
Nweze Justus Amuche; Martins Paul Emenike and Nweze Julius Eyiuche
(How to cite: Nweze J.A.; Martins P.E. and Nweze J.E. (2015). Pathology, pathogenesis and epidemiology of poliovirus.
From https://nwezejustus.wordpress.com/2015/08/06/pathology-pathogenesis-and-epidemiology-of-poliovirus-3/ )
Introduction
Poliomyelitis , also called infantile paralysis is an acute viral infectious disease of the nervous
system that usually begins with general symptoms such as fever, headache, nausea, fatigue, and
muscle pains and spasms and is sometimes followed by a more serious and permanent paralysis of
muscles in one or more limbs, the throat, or the chest. More than half of all cases of polio occur in
children under the age of five. The paralysis so commonly associated with the disease actually affects
less than 1 percent of persons infected by the poliovirus. Between 5 and 10 percent of infected
persons display only the general symptoms outlined above, and more than 90 percent show no signs
of illness at all. For those infected by the poliovirus, there is no cure, and in the mid-20th century
hundreds of thousands of children were struck by the disease every year. Since the 1960s, thanks to
widespread use of polio vaccines, polio has been eliminated from most of the world, and it is now
endemic only in four countries: Nigeria, India, Afghanistan, and Pakistan. Approximately 1,000–2,000
children are still paralyzed by polio each year, most of them in India (“Polio”, 2013).
There are three known serotypes (closely related though distinguishable forms) of wild
poliovirus: PV1, PV2, and PV3. The most widespread serotype is PV1. PV2 likely has been eradicated;
the last PV2 case was reported in 1999 in Uttar Pradesh, India. The third serotype, PV3, is close to
eradication (“Polio”, 2013).
Basic Characteristics of Poliovirus
Poliovirus is a human enterovirus and a member of the family of Picornaviridae. Poliovirus is
composed of an RNA genome and a protein capsid. The genome is a single-stranded positive-sense
RNA genome that is about 7500 nucleotides long. The viral particle is about 30 nanometres in
diameter with icosahedral symmetry. Because of its short genome and its simple composition—only
RNA and a non-enveloped icosahedral protein coat that encapsulates it—poliovirus is widely
regarded as the simplest significant virus (Drutz & Ligon, 2000).
There are three poliovirus serotypes, referred to as type 1, type 2 or type 3. There is minimal
heterotypic immunity between the three serotypes. That is, immunity to one serotype does not
produce significant immunity to the other serotypes. The poliovirus is rapidly inactivated by heat,
formaldehyde, chlorine, and ultraviolet light. Picornaviruses are stable at acid pH and are small,
ether-insensitive viruses with an RNA genome (Centres for Disease Prevention and Control (CDC),
2011).
Pathology and Pathogenesis
The virus enters through the mouth, and primary multiplication of the virus occurs at the site
of implantation in the pharynx and gastrointestinal tract. The virus is usually present in the throat and
in the stool before the onset of illness. One week after onset there is fewer viruses in the throat, but
virus continues to be excreted in the stool for several weeks (CDC, 2012c). Poliovirus replication
occurs in the alimentary tract, followed by a primary, transient presence of viremia. The virus
invades local lymphoid tissue, enters the bloodstream, and then may infect cells of the central
nervous system. Replication of poliovirus in motor neurons of the anterior horn and brain stem
results in cell destruction and causes the typical manifestations of poliomyelitis (CDC, 2011).
The primary determinant of infection for any virus is its ability to enter a cell and produce
additional infectious particles. The presence of CD155 is thought to define the animals and tissues
that can be infected by poliovirus. CD155 is found (outside of laboratories) only on the cells of
humans, higher primates, and Old World monkeys. Poliovirus is however strictly a human pathogen,
and does not naturally infect any other species (although chimpanzees and Old World monkeys can
be experimentally infected). The CD155 gene appears to have been subject to positive selection. The
protein has several domains of which domain D1 contains the polio virus binding site. Within this
domain 37 amino acids are responsible for binding the virus (Mueller & Wimmer, 2003).
Clinically, polio virus transmission is by faecal–oral or occasionally oral–oral routes and the
incubation period is commonly 6 to 20 days with a range of 3 to 35 days. The response to poliovirus
infection is highly variable and has been categorized on the basis of the severity of clinical
presentation (CDC, 2005; 2012c).
According to CDC (2005; 2012c), up to 95% of all polio infections are inapparent or asymp-
tomatic. Estimates of the ratio of asymptomatic to paralytic illness vary from 50:1 to 1,000:1 (usually
200:1). Persons infected but without symptoms shed virus in the stool and are able to transmit the
virus to others.
Approximately 4%–8% of polio infections consist of a minor, nonspecific illness without clinical
or laboratory evidence of central nervous system invasion. This clinical presentation is known as
abortive poliomyelitis, and is characterized by complete recovery in less than a week. The spread
and replication of the virus in other sites such as brown fat, reticuloendothelial tissue, and muscle
causes secondary viremia and leads to the development of minor symptoms. Three syndromes
observed with this form of poliovirus infection are upper respiratory tract infection (sore throat and
fever), gastrointestinal disturbances (nausea, vomiting, abdominal pain, constipation or, rarely,
diarrhea), and influenza-like illness. These syndromes are indistinguishable from other viral illnesses
(CDC, 2012c).
Nonparalytic aseptic meningitis (symptoms of stiffness of the neck, back, and/or legs), usually
following several days after a prodrome similar to that of minor illness, occurs in 1%–2% of polio
infections. Increased or abnormal sensations can also occur. Typically these symptoms will last from 2
to 10 days, followed by complete recovery (CDC, 2012c).
Less than 1% of all polio infections result in flaccid paralysis. Paralytic disease occurs when
the virus enters the central nervous system (CNS) and replicates in motor neurons within the spinal
cord, brain stem, or motor cortex, resulting in the selective destruction of motor neurons leading to
temporary or permanent paralysis. In rare cases, paralytic poliomyelitis leads to respiratory arrest
and death. Paralytic symptoms generally begin 1 to 10 days after prodromal symptoms and progress
for 2 to 3 days. Generally, no further paralysis occurs after the temperature returns to normal. The
prodrome may be biphasic, especially in children, with initial minor symptoms separated by a 1- to 7-
day period from more major symptoms. Additional prodromal signs and symptoms can include a loss
of superficial reflexes, initially increased deep tendon reflexes and severe muscle aches and spasms in
the limbs or back. The illness progresses to flaccid paralysis with diminished deep tendon reflexes,
reaches a plateau without change for days to weeks, and is usually asymmetrical. Strength then
begins to return. Patients do not experience sensory losses or changes in cognition. Many persons
with paralytic poliomyelitis recover completely and, in most, muscle function returns to some degree.
Weakness or paralysis still present 12 months after onset is usually permanent (CDC, 2012c).
Paralytic polio is classified into three types, depending on the level of involvement. Spinal
polio is most common, and during 1969–1979, accounted for 79% of paralytic cases. It is
characterized by asymmetric paralysis that most often involves the legs. Bulbar polio leads to
weakness of muscles innervated by cranial nerves and accounted for 2% of cases during this period.
Bulbospinal polio, a combination of bulbar and spinal paralysis, accounted for 19% of cases. The
death-to-case ratio for paralytic polio is generally 2%–5% among children and up to 15%–30% for
adults (depending on age). It increases to 25%–75% with bulbar involvement (CDC, 2012c).
Persons with residual impairment following paralytic poliomyelitis can develop a condition
called post polio syndrome (PPS), after a period of prolonged stability (usually 30–40 years) (Howard,
2005) in 25% to 40% of these persons (CDC, 2012c). PPS is characterised by exacerbation of existing
muscle weakness with new weakness or paralysis in previously unaffected muscles. Factors that
increase the risk of PPS include, increased period of acute poliovirus infection, presence of
permanent impairment after recovery from acute polio, and female sex (CDC, 2012c). It is believed
that the pathogenesis of PPS is caused by the failure of oversized motor units created during the
recovery process of initial paralytic polio. PPS is rarely life threatening but has a slow, step-wise,
unpredictable course. PPS is not an infectious process and persons who develop the syndrome do not
shed poliovirus (Howard, 2005; CDC, 2012c).
Epidemiology
According to World Health Organization (WHO) (2010), the incidence of poliomyelitis has
been dramatically reduced worldwide, as a result of vaccination, with the WHO aiming to achieve
cessation of all wild poliovirus transmission worldwide by 2013 through an intensified Global Polio
Eradication Initiative. There have been imported poliomyelitis case reports in parts of Southeast Asia,
Eastern Europe and Africa (WHO, 2011). In 1994, the continents of North and South America were
certified to be free of polio, followed by the Western Pacific region (including Australia) in 2000
(WHO, 2000) and the European region in 2002 (WHO, 2002). In countries where the disease
incidence is low but transmission is still occurring, poliomyelitis cases are seen sporadically or as
outbreaks among non-vaccinated persons. Polio cases have decreased by over 99% since 1988, from
an estimated 350 000 cases in more than 125 endemic countries then, to 223 reported cases in 2012.
In the same year, there were still polio cases in Afghanistan, Nigeria and Pakistan (CDC, 2012c). They
also stated that the most recent country to halt transmission was India, which on January 12, 2012,
celebrated one full year with no new reported cases. In 2013, only parts of these three countries in
the world remain endemic for the disease–the smallest geographic area in history–and case numbers
of wild poliovirus type 3 are down to lowest-ever levels. Other countries also have cases of wild-type
poliomyelitis from time to time, due to importation.
According to Global Polio Eradication Initiative (GPEI) (2010), the World Health Assembly has
repeatedly identified Nigeria as the single biggest risk to global polio eradication. It is the only
endemic country with ongoing transmission of both wild poliovirus (WPV) types 1 and 3. (Afghanistan
had no WPV type 3 in 2011, and Pakistan’s last reported case was in June 2011). Multiple factors
have hampered eradication efforts in Nigeria’s northern states. Many are embedded in the country’s
border social-political dynamics, the enduring chasm between government and the governed, and a
decentralized government system that has often neglected service delivery to marginalized
communities. Nonetheless, considerable progress has been made to overcome these challenges
through the application of diplomatic pressure, incentives, new technologies, more comprehensive
and culturally sensitive approaches, and renewed high-level political will.
Until global eradication of polio is achieved, all countries are at risk of polio infection. For
example, in 2005, Indonesia had an imported case of polio, 10 years after the last case of
indigenously acquired poliomyelitis was reported in the country. This imported case of polio caused a
re-establishment of local transmission of the virus and resulted in a large polio epidemic, with more
than 200 cases (Thorley et. al., 2006). Also, a polio outbreak that emerged in April 2010 in Tajikistan was
caused by a strain of PV1 that was very closely related to a strain isolated in Uttar Pradesh, India. Later that
year the virus appeared in Kunduz province in northeastern Afghanistan, which shared a border with
Tajikistan. Both Tajikistan and Kunduz province had been polio-free for more than a decade prior to the 2010
outbreaks. A sudden surge in polio cases and deaths in late October and early November 2010 in Congo
(Brazzaville) raised further concern that poliovirus was spreading from polio-endemic regions. The outbreak in
Congo was believed to have been caused by wild PV1 from India. Major challenges facing efforts to prevent
the spread of the disease to polio-free countries included the hajj and ʿumrah pilgrimages to Mecca, each of
which involved large-scale population movements of people from polio-endemic countries (“Polio”, 2013).
Mass vaccination against polio using intramuscular Salk inactivated polio vaccine (IPV-Salk) –
named after Jonas Salk, first started in Australia in 1956. In 1966, IPV-Salk was replaced by Sabin oral
polio vaccine (OPV-Sabin) –named after Albert Sabin, in the publicly funded immunisation program.
OPV-Sabin is particularly suited to provide mass protection against wild-type polio. Continuing the
polio vaccination program to maintain the current high coverage rate and adequate surveillance for
cases of acute flaccid paralysis remain the best defence against the continuing threat of polio
infection (Roche & Spencer, 2002).
Recognizing both the epidemiological opportunity and the significant risks of potential failure,
the World Health Assembly in May 2012 adopted a resolution declaring the completion of polio
eradication a programmatic emergency for global public health and called for the development of a
comprehensive polio eradication and endgame strategy through 2018 to secure a lasting polio-free
world. Subsequently, the three remaining endemic countries launched national polio emergency
action plans, overseen in each case by the respective head of state, and the partner agencies of the
GPEI also moved their operations to an emergency footing, working under the auspices of the Global
Emergency Action Plan 2012-2013. By the start of 2013, the impact of the emergency approaches is
being seen, with the lowest number of reported cases in fewer districts of fewer countries than at
any previous time. Since then, the new Polio Eradication and Endgame Strategic Plan 2013-2018 has
been developed, in consultation with polio-affected countries, stakeholders, donors, partners and
national and international advisory bodies. The new Plan was presented at a Global Vaccine Summit
in Abu Dhabi, United Arab Emirates, at the end of April 2013. It is the first plan to eradicate all types
of polio disease simultaneously – both due to wild poliovirus and due to vaccine-derived polioviruses
(WHO, 2013).
TABLE. Number of reported non-polio acute flaccid paralysis (NPAFP) cases and acute flaccid paralysis surveillance indicators among children aged <15 years, and oral polio vaccination history among children aged 6–35 months with NPAFP — Nigeria, January 2011–September 2012*
Region/State January–December 2011 January–September 2012
No. of
NPAFP
cases
NPAFP
rate†
Adequate
specimens
(%) §
Zero dose ≥4 doses No. of
NPAFP
cases¶
NPAFP
rate**
Adequate
specimens
(%)
Zero dose ≥4 doses
No. (%) No. (%) No. (%) No. (%)
High-risk
northern
states
2,411 8.6 90 41 (3) 958 (75) 2,261 9.9 90 35 (3) 863 (76)
Bauchi 213 8.6 97 0 (0) 111 (90) 189 9.3 94 3 (3) 72 (78)
Borno 148 6.5 94 9 (11) 51 (60) 139 7.7 96 0 (0) 53 (72)
Gombe 149 12.0 90 0 (0) 66 (93) 186 18.3 93 2 (3) 67 (89)
Jigawa 187 8.3 95 1 (1) 78 (77) 131 7.1 94 0 (0) 38 (72)
Kaduna 171 5.4 89 5 (5) 82 (80) 130 5.0 91 1 (2) 46 (72)
Kano 401 8.1 83 13 (7) 115 (62) 355 8.7 87 14 (8) 116 (65)
Katsina 173 5.7 83 6 (6) 69 (71) 203 8.2 76 5 (4) 82 (71)
Kebbi 205 12.1 85 2 (2) 97 (90) 303 21.8 92 0 (0) 159 (94)
Niger 250 11.9 93 0 (0) 116 (91) 181 10.5 93 1 (1) 84 (92)
Sokoto 190 9.9 93 3 (3) 60 (61) 213 13.5 87 5 (5) 70 (67)
Yobe 136 11.0 92 0 (0) 45 (60) 102 10.0 93 0 (0) 37 (71)
Zamfara 188 10.9 94 2 (2) 68 (70) 129 9.2 98 4 (6) 39 (57)
Other
northern
states††
1,000 9.4 92 11 (2) 411 (80) 1,071 12.4 95 5 (1) 432 (82)
Southern
states§§
2,438 6.9 97 16 (1) 1,025 (75) 2,196 7.6 97 18 (1) 922 (77)
Total 5,849 7.9 93 68 (2) 2,394 (76) 5,528 9.2 94 58 (2) 2,217 (77)
* Data as of October 30, 2012.
† Per 100,000 children aged <15 years.
§ Two stool specimens collected at an interval of ≥24 hours within 14 days of paralysis onset and properly shipped to the laboratory and arriving in good condition.
¶ Includes cases pending final classification as of October 30, 2012.
** Annualized data.
†† Adamawa, Benue, Federal Capital Territory, Kogi, Kwara, Nasarawa, Plateau, and Taraba.
§§ Abia, Akwa Ibom, Anambra, Bayelsa, Cross River, Delta, Ebonyi, Edo, Ekiti, Enugu, Imo, Lagos, Ogun, Ondo, Osun, Oyo, and Rivers.
Adapted from: (CDC, 2012c)
FIGURE 1. Number of cases of wild poliovirus type 1 (WPV1), wild poliovirus type 3 (WPV3), and
circulating vaccine-derived polio virus type 2 (cVDPV2), by month — Nigeria, January 2009–
September 2012*
Adapted from: (CDC, 2012c)
The figure above shows the number of cases of wild poliovirus type 1 (WPV1), wild poliovirus type 3
(WPV3), and circulating vaccine-derived polio virus type 2, by month, in Nigeria during January 2009-
September 2012. During January-September 2012, 99 WPV (82 WPV1 and 17 WPV3) cases were
reported, compared with 38 (28 WPV1 and 10 WPV3) cases during the same period in 2011.
FIGURE 2. Cases of wild poliovirus type 1 (WPV1), wild poliovirus type 3 (WPV3), and circulating vaccine-
derived polio virus type 2 (cVDPV2),* by year — Nigeria, January 2011–September 2012†
Adapted from: (CDC, 2012c)
The figure above shows cases of wild poliovirus type 1 (WPV1), wild poliovirus type 3 (WPV3), and
circulating vaccine-derived polio virus type 2 (cVDPV2), by year, in Nigeria during January 2011-
September 2012. During 2011, a total of 62 WPV (47 WPV1 and 15 WPV3) cases were reported in
Nigeria, compared with 21 (eight WPV1 and 13 WPV3) cases in 2010, an increase of 195%.
REFERENCES
Centers for Disease Control and Prevention. (2005a). Poliomyelitis prevention in the United States:
updated recommendations of the Advisory Committee on Immunization Practices.
Morbidity and Mortality Weekly Report (MMWR), 49 (5), 1–22.
Centers for Disease Control and Prevention. (2005b). Apparent global interruption of wild poliovirus
type 2 transmission. Morbidity and Mortality Weekly Report (MMWR), 50, 222–224.
Centers for Disease Control and Prevention. (2005c). Imported vaccine-associated paralytic
poliomyelitis— United States. Morbidity and Mortality Weekly Report (MMWR), 55, 97–9.
Centers for Disease Control and Prevention. (2011a). Poliomyelitis. In: Atkinson W, Wolfe C,
Hamborsky J, eds. Epidemiology and prevention of vaccine-preventable diseases. 12th ed.
Washington, D.C.: Public Health Foundation.
Centers for Disease Control and Prevention. (2011b). Tracking Progress toward Global Polio
Eradication — Worldwide. Morbidity and Mortality Weekly Report (MMWR), 60 (14), 441-
445.
Centers for Disease Control and Prevention. (2012a). Progress toward interruption of wild poliovirus
transmission – worldwide, January 2011–March 2012. Morbidity and Mortality Weekly
Report (MMWR), 61,353-357.
Centers for Disease Control and Prevention. (2012b). Progress toward poliomyelitis eradication –
Nigeria, January 2011–September 2012. Morbidity and Mortality Weekly Report (MMWR),
61(44), 899-904.
Centers for Disease Control and Prevention. (2012c). Poliomyelitis epidemiology and prevention of
vaccine-preventable diseases. (pp. 1-14). Atllanta G.A. USA. Retrieved from
http://www.cdc.gov/vaccines/pubs/pinkbook/polio.html
Drutz, J.E. and Ligon, B.L. (2000). Polio: its history and its eradication. Seminars in Pediatric Infectious
Diseases, 11, 280-286.
Global Polio Eradication Initiative. (2010). GPEI: Strategic Plan 2010-2012. Retrieved from:
http://www.polioeradication.org/content/publications/gpei.strategicplan.2010-
2012.eng.may.2010.pdf.
Howard, R.S. (2005). Poliomyelitis and the postpolio syndrome. British Medical Journal, 330, 1314-
1318.
Mueller, S. and Wimmer, E. (2003). Recruitment of nectin-3 to cell-cell junctions through trans-
heterophilic interaction with CD155, a vitronectin and poliovirus receptor that localizes to
alpha(v)beta3 integrin-containing membrane microdomains. Journal of Biological
Chemistry, 278(33), 31251–60. doi:10.1074/jbc.M304166200. PMID 12759359.
Polio. (2013). Encyclopædia Britannica. Encyclopædia Britannica Ultimate Reference Suite.
Roche, P. and Spencer, J. (2002). Polio eradication in Australia and the world (editorial).
Communicable Diseases Intelligence, 26, 113-117.
Thorley, B.R., Brussen, K.A., Elliott, E.J., and Kelly, H.A. (2006). Vigilance is required for Australia to
remain polio free. Medical Journal of Australia, 184, 474-475.
World Health Organization. (2002). Certification of poliomyelitis eradication. European region, June
2002. Weekly Epidemiological Record, 77,221-3.
World Health Organization. (2013). Opportunity and risks: an emergency approach. Retrieved from:
http://www.who.int/en/ WHO _ Poliomyelitis.htm.
World Health Organization. (2000). Certification of poliomyelitis eradication. WHO Western Pacific
Region. Weekly Epidemiological Record, 75,399-400.
World Health Organization. (2010). Global polio eradication initiative. Strategic plan 2010–2012.
Geneva: World Health Organization. Retrieved from:
http://www.polioeradication.org/Resourcelibrary/Strategyandwork/Strategicplan.aspx.